As noted in MaryAnn Labant’s article on p. 28, antibody-drug conjugates (ADCs) represent a promising next-generation technology for targeting many diseases. However, as in any evolving technology, there are also a number of challenges as well as trends that continually shape a novel therapeutic approach.
To address these issues, GEN interviewed Thomas Rohrer, Senior Director of Bioconjugate Technology Support, Samsung Biologics America, a fully integrated CDMO.
As noted in MaryAnn Labant’s article on p. 28, antibody-drug conjugates (ADCs) represent a promising next-generation technology for targeting many diseases. However, as in any evolving technology, there are also a number of challenges as well as trends that continually shape a novel therapeutic approach.
To address these issues, GEN interviewed Thomas Rohrer, Senior Director of Bioconjugate Technology Support, Samsung Biologics America, a fully integrated CDMO.
- CDO
- CGMP
- ADC
- Bio Campus
- IR
- CMO
Share article